usdaed

Bank of America, a behemoth whose tendrils reach into the very foundations of American finance, finds itself conspicuously absent from this designated eternity. It is the fourth-largest holding, a substantial weight in Berkshire’s vast portfolio, yet unacknowledged as “core.” One recalls the apocryphal treatise of the Alexandrian scholar, Ptolemy Philometres, who posited that all great fortunes are built upon a foundation of deliberate silences. Berkshire’s involvement began in the aftermath of the Great Recession, a transfusion of capital in 2011 yielding warrants exercised in 2017—a transaction that echoes the alchemical dreams of transforming base metals into gold.

There are, admittedly, a few points in Amarin’s favor. The balance sheet, for instance, is…unburdened. No long-term debt, a cash reserve of nearly $135 million, and short-term investments totaling just under $168 million. This suggests a certain financial robustness, a capacity to sustain operations for a while. (Though, one must always remember that money, like time, is a relentlessly flowing river, and even the most substantial reserves eventually erode. It’s a fundamental principle of the universe, really.) In 2025, Vascepa managed to generate nearly $183 million in revenue. And the aforementioned restructuring has, at least on paper, reduced costs. Management anticipates positive free cash flow in 2026. A debt-free company with positive cash flow is, under normal circumstances, a mildly encouraging sign.

Basically, they’ve cleared house. Sold the lot. It’s a bit like realizing you’ve been dating someone for six months and then they casually mention they’re moving to Mongolia. Unexpected. And potentially expensive.

This reduction lowers InterDigital’s weight to 3.71% of the fund’s total assets, a descent from the previous 4.947%. One is reminded of a celestial sphere, where the relative brightness of a star signifies not its inherent power, but its proximity to the observer. The fund’s other significant holdings – $282.09 million in SMCI and $281.40 million in EXE – remain steadfast, like fixed points in a fluctuating cosmos.

But let’s not rush to judgment. BJ’s possesses a certain… allure. A valuation, if you will, that’s considerably more approachable than Walmart’s. Which begs the question: do you favor the well-oiled machine, even if it’s a bit pricey, or the slightly smaller, more reasonably valued contender? It’s a classic portfolio dilemma, really.

Regencell, it appears, is an ‘early stage bioscience company.’ Which, translated from the jargon, means they are researching drugs that might show promise. Emphasis on ‘might.’ As yet, nothing has actually materialized. It’s a high-risk area, naturally, best left to those with a positively reckless disregard for capital. One doesn’t dabble in such things without a strong stomach and an even stronger aversion to common sense.

The fund, you see, has now devoted a rather significant 5.78% of its resources to this digital grocery enterprise. A bold move, perhaps, but one that suggests a confidence in the company’s prospects. One can scarcely blame them, considering the modern penchant for having one’s provisions delivered directly to the doorstep, thereby avoiding the rigmarole of actually going to the shops.

The exchange, that cathedral of ambition, had always been a place where fortunes were built on the shifting sands of probability. The S&P 500, a benevolent deity to some, a capricious tyrant to others, had never known a twenty-year winter, its growth a relentless tide. The Dow Jones, a stoic elder, and the Nasdaq, a restless youth, often mirrored its ascent, their trajectories tracing the dreams and anxieties of a nation. But even deities are not immune to the storms that gather on the horizon.

Revenue, it seems, ascended by 28% year over year to $444.3 million in their fiscal 2026 fourth quarter, concluding on January 31st. Adjusted earnings, rather impressively, soared 115% to $0.56 per share. One almost feels compelled to applaud, though one wouldn’t dream of actually doing so.